Q3 2025 Management View Richard Lowenthal, Co-Founder, President, CEO & Director, highlighted a pivotal quarter for ARS ...

Fredun Pharmaceuticals Limited announced impressive financial growth in Q2 FY26, with a 35.34% YoY increase in total income.

With strong returns on capital employed clubbed with high dividend yields, they are letting their investors know, they are in ...

Analysts estimate that ARS Pharmaceuticals will report an earnings per share (EPS) of $-0.47. ARS Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, ...

JB Pharma reported a 19% net profit rise to ₹207.8 crore, driven by strong domestic sales of Cilacar, Metrogyl, Nicardia, ...

Discover why ANIP may beat earnings estimates again, expand with new drug approvals, and raise 2025 guidance. Click here to ...

The company's annualized recurring revenue run rate jumped 30% year over year in Q3 to $2 billion. Its gross payment volume ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to ...

Catalyst Pharmaceuticals (CPRX) shares have moved modestly in recent sessions, sparking fresh questions about its long-term value and growth prospects. Investors appear focused on underlying ...

Alembic Pharmaceuticals reported a strong second quarter with profit rising 21% year-on-year to ₹185 crore, supported by ...

By Rishika Sadam and Kashish Tandon (Reuters) -Sun Pharmaceutical Industries, India's top drugmaker by revenue, reported ...